EMBC
Embecta Corp.11.89
-0.04-0.34%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Q&A clarifies pricing hit, GLP-1 upsides
Q&A unpacked US pricing headwinds from customer mix shifts and channel dynamics, partially offset by advance orders, while volumes proved stable year-over-year—better than feared. International gains traced to execution, including a new large Latin America customer, fueling H2 optimism and countering US softness to keep guidance at the low end. GLP-1 enthusiasm held firm, with Zepbound's QuickPen approval flagged as fresh upside beyond the $100M opportunity. Pen injector project stays early-stage, no timelines shared. Answers reaffirmed prepared remarks with added color. Investors watch China traction, international momentum.
Key Stats
Market Cap
695.72MP/E (TTM)
7.34Basic EPS (TTM)
1.62Dividend Yield
0.05%Recent Filings
8-K
Embecta acquires Owen Mumford
Embecta signed a definitive agreement on March 19, 2026, to acquire UK-based Owen Mumford Holdings for £100 million upfront cash—subject to adjustments—plus up to £50 million in Aidaptus® sales milestones through 2028. The deal targets drug-delivery expansion and chronic care devices, leveraging embecta's global reach; Owen Mumford posted £69.4 million revenue in FY2025. Closing eyed for Q3 2026 fiscal. Expect revenue boost from 2027.
8-K
Annual meeting results
Embecta Corp. held its 2026 Annual Meeting on February 11, electing all seven director nominees, including Carrie L. Anderson and Christopher R. Reidy, with strong support despite some opposition to Reidy (2.7M against). Stockholders ratified Ernst & Young as auditors (53M for), approved executive comp advisory (47.7M for), and passed equity plan amendment (41.4M for). Continuity intact.
10-Q
Q1 FY2026 results
Embecta held revenues steady at $261.2M for Q1 FY2026 ended December 31, 2025, down 0.3% y/y, yet gross margin expanded to 61.9% from 60.0% on lower cost of products sold. Operating income surged to $83.3M from $28.7M, fueled by slashed R&D ($4.6M vs $20.3M) after axing the patch pump and a $10.1M gain on selling related IP. Diluted EPS hit $0.74 on 59.3M shares, matching net income of $44.1M. Cash fell to $201.3M after $37.5M debt paydown on $1.4B total debt (6.1% rate), with $17.2M operating cash flow and $500M revolver undrawn. Free cash flow generated $16.6M (derived). Solid covenant compliance holds. Pricing pressures persist.
8-K
Q1 revenues flat, EBITDA steady
Embecta reported Q1 FY2026 revenues of $261.2M, down 0.3% reported but flat on adjusted EBITDA at $97.2M (37.2% margin), boosted by a $10.1M gain from discontinued patch pump assets while U.S. sales dropped 7.6%. International revenues rose 8.4%, offsetting declines. Debt fell $37.5M; full-year guidance holds steady. Results met expectations.
8-K
Q4 revenue dips, margins surge
Embecta reported Q4 revenues of $264M, down 7.7% year-over-year amid U.S. declines and China headwinds, yet GAAP operating margin soared to 21.4% from 9.2% while adjusted EBITDA margin hit 34.1%. Full-year revenue fell 3.8% to $1.08B, but debt plunged $184.5M and free cash flow surged to $182M. FY26 guides flat-to-slightly-down revenue growth. Debt paydown frees growth capital.
IPO
Website
Employees
Sector
Industry
BBNX
Beta Bionics, Inc.
29.63-0.09
BDX
Becton, Dickinson and Company
196.39-3.70
ECIA
Encision, Inc.
0.15+0.00
EMED
Electromedical Technologies, In
0.00+0.00
EMPG
Empro Group Inc.
17.36+0.00
ENOV
Enovis Corporation
26.07-0.47
GCTK
GlucoTrack, Inc.
5.18+0.03
MODD
Modular Medical, Inc.
0.34-0.03
NMTC
NeuroOne Medical Technologies C
0.71+0.05
SENS
Senseonics Holdings, Inc.
6.62-0.17